CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 227 enrolled
Drug / intervention
vortioxetine 10 mg tablet +2 moredrug
Likely dose
vortioxetine 10 mg tabletfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02327013
NCT02327013Phase 2Completed
CompareCT.gov

Interventional, Randomised, Double-blind, Placebo-controlled, Fixed-dose Study of Vortioxetine in Adults With Attention Deficit Hyperactivity Disorder (ADHD)

H. Lundbeck A/S·interventional·Posted Dec 30, 2014·Updated Mar 7, 2018

In Brief

A Phase 2 clinical trial evaluating vortioxetine 10 mg tablet, vortioxetine 20 mg tablet, and 1 other intervention for Attention Deficit Hyperactivity Disorder. Completed, enrolled 227 participants across 15 sites.

Detailed Summary

The purpose is to determine the effect of vortioxetine treatment on ADHD symptoms in adult patients with ADHD in a 12 weeks study.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAttention Deficit Hyperactivity Disorder
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
First PostedDec 30, 2014
Enrollment StartDec 1, 2014
Primary CompletionSep 1, 2016
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 11.5 years ago

Interventions

vortioxetine 10 mg tabletdrug

Oral tablets, once daily

vortioxetine 20 mg tabletdrug

Oral tablets, once daily

Placebo tabletother

Oral tablets, once daily